Clinical Trials

BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

490 enrolled

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Ureteral Neoplasms, Urologic Neoplasms, Triple Negative Breast Neoplasms

NCT06691984 2026-05-15

Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)

707 enrolled

Neoplasms, Prostatic Neoplasms

NCT06970847 2026-05-14

AMPLIFY

220 enrolled

Prostatic Neoplasms

NCT04905069 2026-05-12

SABRE

500 enrolled

Neoplasms, Prostatic Neoplasms

NCT06451614 2026-05-12

HYDROSPACE

230 enrolled

Prostatic Neoplasms

NCT01946204 2026-05-11

SPARTAN

1,207 enrolled 15 charts 1 FDA

Prostatic Neoplasms

NCT02257736 2026-05-11

An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)

982 enrolled 15 charts

Prostatic Neoplasms

NCT02489318 2026-05-11

TITAN

1,052 enrolled 13 charts 1 FDA

Phase 4 Active not recruiting

Prostatic Neoplasms

NCT04108208 2026-05-11

A Study of Apalutamide in Chinese Participants With Non Metastatic Castration Resistant Prostate Cancer (NM-CRPC)

75 enrolled 9 charts

Prostatic Neoplasms

NCT04122976 2026-05-11

DAROL

805 enrolled

Prostatic Neoplasms

NCT02123758 2026-05-08

A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer

57 enrolled

Prostatic Neoplasms

NCT02531516 2026-05-08

An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS

1,503 enrolled

Prostatic Neoplasms

NCT03523442 2026-05-08

A Study of Androgen Receptor (AR) Antagonist Apalutamide in Chinese Participants With Metastatic Castration-Resistant Prostate Cancer

19 enrolled

Prostatic Neoplasms

NCT03767244 2026-05-08

PROTEUS

2,517 enrolled

Prostatic Neoplasms

NCT04557059 2026-05-08

PRIMORDIUM

692 enrolled

Prostatic Neoplasms

NCT04577833 2026-05-08

A Study of Comparative Formulations of Niraparib and Abiraterone Acetate (AA) in Men With Prostate Cancer

136 enrolled

Prostatic Neoplasms

NCT04644770 2026-05-08

A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer

144 enrolled

Adenocarcinoma, Prostatic Neoplasms

NCT04662580 2026-05-08

ARX517

183 enrolled

Prostatic Neoplasms

NCT04898634 2026-05-08

A Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer

216 enrolled

Prostatic Neoplasms

NCT02319837 2026-05-07

Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)

1,068 enrolled 20 charts 1 FDA

Prostatic Neoplasms

NCT04493853 2026-05-05

CAPItello-281

1,012 enrolled

Prostatic Neoplasms

NCT05067140 2026-05-05

A Study of ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer

152 enrolled

Genital Neoplasms, Male, Prostatic Neoplasms, Urogenital Neoplasms

NCT06551324 2026-05-05

MEVPRO-1

600 enrolled

Prostatic Neoplasms, Recurrence

NCT06651632 2026-05-04

WATER IV PCa

280 enrolled

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT05059236 2026-05-01

ARASEC

223 enrolled

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT07047118 2026-05-01

A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

138 enrolled

Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant

NCT04597411 2026-04-30

Study of 225Ac-PSMA-617 in Men With PSMA-positive Prostate Cancer

101 enrolled

Genital Diseases, Male, Genital Neoplasms, Male, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms, Prostatic Neoplasms, Castration-Resistant

NCT05983198 2026-04-29

SatisfACtion

33 enrolled

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT06395753 2026-04-28

A Dose Finding Study of Debio 4228 in Participants With Advanced Prostate Cancer

66 enrolled

Phase 2/3 Active not recruiting

Prostatic Neoplasms

NCT03706365 2026-04-24

CYCLONE 2

393 enrolled 23 charts

Prostatic Neoplasms

NCT04521686 2026-04-22

Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations

BreastCNSDermatologicGastrointestinalGenitourinaryHead & NeckSarcoma

200 enrolled

Breast Neoplasms, Chondrosarcoma, Colonic Neoplasms, Glioblastoma, Glioma, Melanoma, Prostatic Neoplasms, Thyroid Neoplasms, Central Nervous System Neoplasms, Cholangiocarcinoma

NCT06545942 2026-04-17

Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors

BreastGastrointestinalGenitourinaryGynecologic

220 enrolled

Breast Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

NCT07236112 2026-04-15

Study of TRDC002 in the Diagnosis of Patients With PSMA-positive Prostate Cancer

6 enrolled

Prostatic Neoplasms

NCT05683691 2026-04-13

VAPOR 2

400 enrolled

Prostatic Neoplasms

NCT05467176 2026-04-08

OPTYX

999 enrolled

Prostatic Neoplasms

NCT04821622 2026-04-07

Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC

599 enrolled

Prostatic Neoplasms

NCT07214961 2026-04-07

ARTISAN

80 enrolled

Neoplasm Metastasis, Prostatic Neoplasms

NCT07344779 2026-04-03

ROAD

1,600 enrolled

Prostatic Neoplasms

NCT03860272 2026-03-30

Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer

GastrointestinalGenitourinaryGynecologicSarcomaThoracic

499 enrolled

Fibrolamellar hepatocellular carcinoma, Carcinoma, Non-Small-Cell Lung, Hemangiosarcoma, Ovarian Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms

NCT04689828 2026-03-23

PSMAfore

469 enrolled 11 charts 1 FDA

Prostatic Neoplasms

NCT07038369 2026-03-17

A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations

BreastGenitourinaryGynecologic

134 enrolled

Breast Diseases, Breast Neoplasms, Uterine Cervical Neoplasms, Genital Neoplasms, Female, Neoplasms, Neoplasms by Site, Ovarian Neoplasms, Prostatic Neoplasms, Urogenital Neoplasms, Uterine Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT05546268 2026-03-03

Study of Oral MRT-2359 in Selected Cancer Patients

BreastGenitourinaryLymphoidThoracic

174 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Prostatic Neoplasms, Lymphoma, Large B-Cell, Diffuse, Small Cell Lung Carcinoma

NCT04471727 2026-02-24

MK-6070-001

EndocrineGenitourinaryNETThoracic

232 enrolled

Lung Neoplasms, Prostatic Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors, Small Cell Lung Carcinoma

NCT04644068 2026-02-19

PETRA

BreastGastrointestinalGenitourinaryGynecologicThoracic

702 enrolled

Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT04478279 2026-02-09

A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors

BreastCNSDermatologicGenitourinary

125 enrolled

Brain Neoplasms, Breast Neoplasms, Glioblastoma, Melanoma, Prostatic Neoplasms

NCT04964271 2026-02-02

Identification of Prostate Cancer Specific Markers in Patients Compared to Healthy Participants

60 enrolled